STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · MCOV-B.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Medicover AB (publ)’s forward annual dividend is SEK 2.20 per share, paid annual. The forward yield is 0.79% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Medicover AB (publ)’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of SEK 1.87. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medicover AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Mar 31, 2025 | SEK 1.46+50.36% vs estimate | SEK 6.36B+1.7% vs estimate |
|---|
| Q2 2024 | Sep 30, 2024 | -SEK 0.33-141.94% vs estimate | SEK 6.00B+2.68% vs estimate |
|---|
| Q4 2023 | Jun 30, 2024 | SEK 0.48-30.31% vs estimate | SEK 5.79B+0.39% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 341.60+SEK 2.80 (+0.83%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 40.85+SEK 0.60 (+1.49%)
Vimian Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.85% below the high.
SEK 116.80-SEK 1.30 (-1.1%)
Attendo AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.29% below the high.
SEK 183.30-SEK 2.80 (-1.5%)
Ambea AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 3.42% below the high.
SEK 70.90+SEK 0.30 (+0.42%)
Humana AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.87% below the high.
SEK 58.00-SEK 1.50 (-2.52%)
Devyser Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 56.91% below the high.
